Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Open-Angle Glaucoma
Interventions: bimatoprost 0.03%, dorzolamide 2%/timolol maleate 0.5% fixed combination, placebo; Drug
Lead sponsor: Pharmaceutical Research Network; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Louisville, Kentucky • Mt. Pleasant, South Carolina • Houston, Texas

Conditions: Age-related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions: Visual acuity (presenting and pinhole), Optical coherence tomography (OCT), Intraocular pressure, Active linkage to care, Fundus Photography; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older
Enrollment: 60,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Trabodenoson, Latanoprost, Timolol; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Bristol, Tennessee

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Carl Zeiss Meditec, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Palo Alto, California • Miami, Florida • Dallas, Texas + 1 more

Conditions: Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions: dorzolamide/timolol; Drug
Lead sponsor: CT Glaucoma Associates; Other
Eligibility: 25 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Norwalk, Connecticut

Conditions: Eye Diseases
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Denver, Colorado • Bethesda, Maryland

Conditions: Glaucoma
Interventions: Baerveldt implant, Trabeculectomy with mitomycin C; Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 16
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 13 more

Conditions: Glaucoma Open-Angle
Interventions: Glaucoma surgery; Device
Lead sponsor: PLU Ophthalmic; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Travoprost Ophthalmic Topical Cream low-dose, Travoprost Ophthalmic Topical Cream mid-dose, Travoprost Ophthalmic Topical Cream high-dose, Timolol maleate ophthalmic solution, 0.5%, Travoprost Ophthalmic Solution, 0.004%; Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.03% Formulation B Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma
Interventions: Rho-Kinase Inhibitor (AR-12286); Drug
Lead sponsor: New York Glaucoma Research Institute; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Ocular Hypertension, Open-angle Glaucoma
Interventions: AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: Up to 99 Years
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glaucoma, Angle-Closure, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Ocular Hypertension
Interventions: Scleral Lens; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glaucoma, Ocular Hypertension
Interventions: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
Interventions: nGoggle; Device
Lead sponsor: NGoggle; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 200 participants
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glaucoma, Ocular Hypertension, Open Angle Glaucoma
Interventions: Nanodropper; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma
Interventions: Silicone plate Ahmed Glaucoma Valve (Model FP7), Porous Plate Ahmed Glaucoma Valve (Model M4); Device
Lead sponsor: Peter Netland, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Glaucoma
Interventions: standard of care, education; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
Interventions: Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®); Drug
Lead sponsor: YS Life Science Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Beverly Hills, California • Inglewood, California • Newport Beach, California + 9 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Glaucoma
Interventions: Sulcus tube placement, Anterior chamber (AC) tube placement; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: San Francisco, California • Walnut Creek, California • Miami, Florida + 4 more

Conditions: Glaucoma
Interventions: Surgery, Selective Laser Trabeculoplasty; Procedure
Lead sponsor: University of Kentucky; Other
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Lumigan Versus Cosopt

Village-Integrated Eye Worker Trial II

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in Glaucoma

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases

Tube Versus Trabeculectomy (TVT) Study

A Prospective Interventional Cohort Study to Evaluate the Efficacy and Safety of the AquaLumen, a Novel Filtration Procedure for the Treatment of Open Angle Glaucoma

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

Intraocular Pressure (IOP) Changes Associated With Muslim Prayer Postural Changes

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

Intraocular Pressure in Ocular Hypertensives With Scleral Lens Wear

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Assessment of Visual Function With a Portable Brain-computer Interface

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves

Effect of Glaucoma Educators on Adherence to Prescribed Therapeutic Regimens in Glaucoma Patients

A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

Effects of Selective Laser Trabeculoplasty